Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Apr 2023
The treatment of chronic thromboembolic pulmonary hypertension with balloon pulmonary angioplasty has an evolving safety profile over the years, from 2013 to 2022, as revealed by an analysis of more than two dozen studies.
Read Full NewsBrexpiprazole is linked to reduced symptoms, improved functioning, and greater response compared with placebo in patients with early-episode schizophrenia, new research shows.
But the CMS’s cancer-focused alternative payment model’s losses “mask successes” that should serve as lessons, experts say.
1.
Train Eyes so Myopia Doesn't Get Worse? Nurse Intervention for BP Post-Stroke
2.
Characterizing metastatic disease during adaptive therapy by using dynamic biomarkers and mathematical modeling.
3.
Algorithm that predicts pancreatic cancer metastasis could help avoid unnecessary surgeries
4.
C/EBP? works in tandem with MYB to sustain AML cells' oncogenic program.
5.
Nasal therapeutic HPV vaccine could prevent cervical cancer
1.
How Prevident is Revolutionizing Oral Care
2.
Case Study: The Role of JAK Inhibitors in Myeloproliferative Disorders
3.
Getting to Know RDW and SD: How They Relate to Anemia, Inflammation, and More
4.
The Impact of Microadenoma on Hormonal Health
5.
Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
3.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge